Refacto Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increased diagnosis of hemophilia a, transition from plasma-derived to recombinant therapies, expansion of hemophilia treatment centers, improved patient survival rates, clinical validation of factor viii therapies.

The growth in the forecast period can be attributed to expansion of long-acting clotting factor products, rising demand for personalized hemophilia care, increasing investments in recombinant biologics, growing focus on home-based treatment models, advancements in gene and protein therapy integration. Major trends in the forecast period include increasing adoption of recombinant clotting factors, expansion of prophylactic hemophilia treatment, growing use of pre-filled syringe formats, enhanced focus on bleeding prevention protocols, improved manufacturing yield of recombinant proteins.

The increasing healthcare expenditure is expected to drive the growth of the Refacto market moving forward. Healthcare expenditure refers to the total spending on medical services, products, and public health initiatives aimed at maintaining and improving health. This expenditure is rising due to factors such as an aging population requiring more medical care and the growing prevalence of chronic diseases like diabetes and heart conditions. Healthcare spending on Refacto drugs supports their development, production, and accessibility for treating hemophilia and related conditions. Rising healthcare expenditure benefits Refacto by driving demand for advanced therapies like Refacto, which in turn improves access to treatment, promotes long-term cost savings through reduced hospitalizations and complications, and enhances patient adherence to therapy. This ultimately contributes to market growth. For example, in May 2023, a report from the Office for National Statistics, a UK-based government agency, showed that healthcare spending in the UK rose by 5.6% between 2022 and 2023, a significant increase from the 0.9% growth in 2022, with total healthcare expenditure reaching approximately $317.63 billion (£292 billion) in 2023. As a result, the increase in healthcare expenditure is driving the growth of the Refacto market.

The rising prevalence of hemophilia A is expected to drive the growth of the Refacto market in the future. Hemophilia A is a genetic bleeding disorder caused by a deficiency of clotting factor VIII, leading to impaired blood clotting and prolonged bleeding, even from minor injuries. The prevalence of hemophilia A is increasing, mainly due to enhanced diagnostic capabilities that are identifying more cases with greater accuracy. Refacto supports the management of hemophilia A by replacing the missing factor VIII, improving blood clotting, and reducing bleeding episodes, thereby enabling better long-term disease management. For example, in May 2024, the US Centers for Disease Control and Prevention (CDC) estimated that 33,000 males in the United States are living with hemophilia. Therefore, the increasing prevalence of hemophilia A is contributing to the growth of the Refacto market.

The growing number of drug approvals is also expected to propel the growth of the Refacto market in the future. Drug approvals refer to the regulatory process in which agencies assess and authorize a drug for public use, ensuring it meets safety, efficacy, and quality standards. The rise in drug approvals is attributed to advancements in technology, more streamlined regulatory processes, greater investment in biotechnology, and a focus on rare diseases and personalized medicine. Refacto plays a role in facilitating drug approvals by serving as a proven recombinant therapy for hemophilia A, demonstrating consistent safety and efficacy in clinical trials, which supports regulatory confidence and accelerates the approval of similar innovative treatments in the hemophilia market. For instance, in January 2024, the National Institutes of Health, a U.S.-based government agency, reported that in 2023, the U.S. Food and Drug Administration (FDA) approved 55 new drugs, compared to 37 drugs approved in 2022. Therefore, the increasing number of drug approvals is contributing to the growth of the Refacto market.

Major companies operating in the refacto market are Pfizer Inc.

North America was the largest region in the refacto market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the refacto market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the refacto market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the refacto market by increasing costs of imported bioreactors, purification systems, sterile filling equipment, and cold-chain logistics required for recombinant factor viii production. North America and Europe are significantly affected due to dependence on specialized imported biologics manufacturing infrastructure, while emerging markets face higher acquisition costs. These tariffs are raising production and therapy delivery expenses. However, they are also driving domestic biologics manufacturing expansion, regional supplier development, and long-term supply security for hemophilia treatments.

The refacto market research report is one of a series of new reports that provides refacto market statistics, including refacto industry global market size, regional shares, competitors with a refacto market share, detailed refacto market segments, market trends and opportunities, and any further data you may need to thrive in the refacto industry. This refacto market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Refacto is a recombinant factor VIII product used to treat hemophilia A, a genetic disorder in which patients lack sufficient clotting factor, leading to prolonged bleeding. It works by replacing the missing factor VIII, helping to prevent or control bleeding episodes in affected individuals.

The primary clinical indications for Refacto include prophylaxis, on-demand treatment, perioperative management, and immune tolerance induction (ITI). Prophylaxis is a treatment approach aimed at preventing a medical condition from occurring. In the case of hemophilia, prophylactic treatment involves regular infusions of clotting factor concentrates to prevent bleeding episodes before they happen. Refacto is available in various formulations, including powder for injection and pre-filled syringes, and is distributed through hospital pharmacies, retail pharmacies, and specialty pharmacies. It is used by a wide range of patients, including pediatric, adult, and geriatric populations.

The refacto market consists of sales of products including recombinant factor VIII products, extended half-life recombinant factor VIII products, and plasma-derived factor VIII products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.